Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Oral Abuse Potential of Nalbuphine Solution and Extended-Release Intact Tablets in Non-Dependent, Recreational Opioid Users

NCT04018664 is registered in ClinicalTrials.gov with Trevi Therapeutics as lead sponsor.

NCT NCT04018664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04018664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Oral Abuse Potential of Nalbuphine Solution and Extended-Release Intact Tablets in Non-Dependent, Recreational Opioid Users
Lead sponsor
Trevi Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 29, 2018
Completion date
June 2, 2020
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nalbuphine, opioid abuse